ASKC202 / Aosaikang Pharma - LARVOL DELTA

Phase I dose escalation of ASKC202, a novel cMET tyrosine kinase inhibitor, in patients with advanced solid tumors (AACR 2024) - P1 | "One subject (150mg QD) with MET missense mutation (p.S186L) had a 67% tumor reduction in intracranial lesion from baseline. Exposure of ASKC202 increased dose-proportionally at dose range 50mg to 300mg, but less than dose-proportionally increased at 300mg to 600mg.Conclusions ASKC202 monotherapy was well-tolerated with manageable safety profile and showed anti-tumor signal and the central nervous system efficacy."

Clinical • Metastases • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MET

Aosaikang: The combination of ASKC202 tablets and ASK120067 tablets has been approved for clinical trials [Google translation] (Stockstar) - "Securities Times e company news, Aosaikang...announced on the evening of November 12 that the clinical trial of the combination of ASKC202 tablets and ASK120067 tablets submitted by Jiangsu Aosaikang Pharmaceutical, a wholly-owned subsidiary of the company, has recently received a clinical trial certificate issued by the State Food and Drug Administration. The trial approval notice agrees to conduct a clinical trial of ASKC202 tablets in combination with ASK120067 tablets for advanced solid tumors."

New trial • Oncology • Solid Tumor

Aosaikang: Subsidiary drug clinical trial application accepted [Google translation] (Daily Economic News - NBD) - "...Aosaikang announced that the clinical trial application for the combination of the subsidiary's innovative drug ASKC202 tablets and ASK120067 tablets has been accepted."

New trial • Oncology

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: May 2022 ➔ Aug 2022

Enrollment open • Metastases • Trial initiation date • Gastrointestinal Cancer • Oncology • Solid Tumor • MET

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 (clinicaltrials.gov) - P1 | N=150 | Not yet recruiting | Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd.

New P1 trial • Gastrointestinal Cancer • Oncology • Solid Tumor • MET